Inflammatory and Demyelinating Diseases Flashcards

1
Q

Subtypes of MS

describe relapsing-remitting

A

sporadic episodes of new or worse symptoms over 2-10 days with varied improvement after 1-6 months

85%

younger age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Subtypes of MS

primary progressive

A

progressive without true relapses
15%

middle age

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Subtypes of MS

secondary progressive

A

relapsing remitting that converts to progressive

50% of RR MS will convert

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Subtypes of MS

relapsing progressing

A

both relapse and progressive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Subtypes of MS

clinically isolated syndrome

A

single first attack of apparent demyelination

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Subtypes of MS

radiologically isolated syndrome

A

individuals scanned for non-MS show MS on MRI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

most MS what age?

what gender?

what race?

closer or further from equator

MS most common cause of __

A

15-45 y/o

women

Caucasian

further from equator

CNS inflamm disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

typical clinical symptoms early in MS

A

unifocal at first (one eye, single cord)

1) paresthesias
2) weakness
3) monocular loss of vision/diplopia
4) gait problems
5) lhermitte’s sign
6) urinary urgency/frequency
7) constipation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

describe lhermitte’s sign

A

tinging down spine when flex neck

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

late symptoms in MS

A

multifocal

1) early +
2) fatigue
3) sex problems
4) depression
5) cognitive dysfunction
6) pain
7) dysphagia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

neuro exam abnormalities

A

1) asymm UMN signs
2) decr visual acuity and optic atrophy
4) afferent pupillary defect
5) eye movement problems and INO (adduct impairment)
7) sensory loss
8) cerebellar signs
9) labile affect
10) cog dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

describe INO

A

adduction impairment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

MRI changes
where are lesions?

T1 holes means

T1 contrast enhancing lesions means?

A

in periventricular, corpus callosum, juxtacortical regions, spinal cord, brainstem, cerebellum

holes means chronic axonal damage

contrast lesions means breakdown BBB (early sign = 2-6 wks)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

MRI changes
T2 bright lesions means?

atrophy occurs where

A

hyperintense/bright lesions

acute + chronic (volume = burden of disease)

atrophy in decr parenchyma, incr ventricles, incr subarachnoid space

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

MRI changes

most predictive of disability

A

T1 holes and atrophy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

CSF of MS

A

normal to slight elev protein 4 oligoclonal bands in CSF not blood

Lipid-specific IgM bands = bad prognostic bands

17
Q

MS

evoked potentials in primary progressive MS

A

prolonged potentials in primary progressive MS = demyelination
in brainstem, visual, somatosensory

18
Q

MS
OCT for?

level fo myelin specific protein

A

optic nerve damage

elevated myelin protein but nonspecific

19
Q

MS

lumbar punctures done when

A

primary progressive MS

20
Q

drugs for acute attacks

A

high dose steroids (methylprednisolone +/- prednisone taper)

plasma exchange for severe myelination unresponsive to steroids

21
Q

Immunotherapy for relapsing remitting MS

A
ABC-R therapy (avonex, betaseron, copaxone, rebif)
IFNbeta 1a
IFNbeta 1b
glutiramer acetate
IFNbeta 1a
22
Q

mechanism of Fingolimod for relapsing remitting MS

side effects

A

reacts with sphingosine-1-phos receptors to trap lymphocytes in lymph nodes

bradycardia
macular edema
infection

23
Q

natalizumab shown to cause

A

PML by reactivation of JC virus

24
Q

immunotherapy for secondary progressive MS

A

IFN beta-1b (betasaron) and

ABC-R

25
Q

treatment of gait/motor function in MS

A

dalfampridine (Ampyra)

26
Q

effect of ABC-R treatment

A

decr in # of enhancing lesions, (T2 burden)
decr brain atrophy
decr disability progression

27
Q

most effect use of abc-r tx in sp ms

A

young pts with short disease duration with inflamm

28
Q

type IV subtype in white matter only seen where

A

type IV only seen in primary

progressive MS

29
Q

active sign of inflamm

A

myelin degradation products in macrophages

active = dense infiltration of macrophages throughout lesion

Chronic = broad rim of macrophages at edge and macrophages with later stages of myelin degradation products

30
Q

HLA assoc of MS

A

HLA-DR2

and IL-7 and IL-2 receptors

31
Q

environmental causes of MS

A

1) EBV via B lymphocyte
2) cigarette smoking
3) vitamin D deficiency
4) obesity
5) high salt worse progression but not develop disease

32
Q

diffeence btwn cns lesions in RMS and PPMS

A

RRMS = 2 attacks 30+ days apartment

PPMZS = minimum 12 months of progression with disseminated lesions in space

33
Q

early lesions on T1

A

hypointesne with leakage of contrast due to BBB damage

enhance for 2-6 weeks then BBB fixed

34
Q

define dawson’s fingers

A

lesion perpendicular to long axis of ventricles

35
Q

over time what happens in brian in T1 MS

A

holes

atrophy with incr ventricles due to hydrocephalus ex vacuo

36
Q

spinal cord impact of MS

A

cigar shaped short lesions (one segments)

contrast enhancing in posterior column

37
Q

neuromyelitis optica on MRI

A

3+ or more segments long with swelling and present with pain in mid back

track back up medulla

hypodense –> cord massively swollen

38
Q

bad prognostic signs in MRI

A
–  Atrophy, especially gray matter
–  High T1 Burden of Disease (T1 holes) 
–  High T2 Burden of Disease
–  Posterior fossa lesions
–  Spinal cord lesions